Related Experiment Video
Updated: Dec 21, 2025

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
Simultaneous administration of imipenem/cilastatin/relebactam with selected intravenous antimicrobials, a stewardship
Islam M Ghazi1, Wasim S El Nekidy2, Regan Asay1
1Philadelphia College of Pharmacy, University of the Sciences, Philadelphia, PA, United States of America.
Abstract:
Imipenem/cilastatin/relebactam is a β-lactam/β-lactamase inhibitor that has been recently FDA approved for complicated intra-abdominal and urinary tract infections under the brand name Recarbrio®. It has activity against imipenem non-susceptible Pseudomonas species as well as KPC-producing Enterobacteriaceae. Optimization of PK/PD of antimicrobials particularly in critically-ill patients is essential, but unfortunately, is hindered by separate administration that requires significant resources. The objective of the study is to investigate the compatibility of Y-site administration of imipenem/cilastatin/relebactam with a wide range of antimicrobials. After admixture, physical characteristics, pH changes and turbidity were measured for each 2-drug combination at a time. With the exception of amphotericin B deoxycholate, and posaconazole, imipenem/cilastatin/relebactam was compatible with a variety of antimicrobial agents. The compatibility profile described, will facilitate incorporation into hospital protocols, contribute to therapy optimization and guide clinicians to avoid successive administration, consequently resulting in reduction of total infusion time, optimization of PK/PD, economizing nursing time and cost containment.
Insights
Imipenem/cilastatin/relebactam (Recarbrio®) is compatible with most antimicrobials for Y-site administration, simplifying treatment for severe infections. This compatibility study supports optimized drug administration, reducing infusion times and healthcare costs.
Area of Science:
- Pharmacology
- Infectious Diseases
- Clinical Pharmacy
Background:
- Imipenem/cilastatin/relebactam (Recarbrio®) is FDA-approved for complicated infections.
- It targets resistant bacteria like imipenem-non-susceptible Pseudomonas and KPC-producing Enterobacteriaceae.
- Optimizing antimicrobial pharmacokinetics/pharmacodynamics (PK/PD) in critically ill patients is crucial but challenging due to separate administration needs.
Purpose of the Study:
- To assess the Y-site administration compatibility of imipenem/cilastatin/relebactam with various antimicrobial agents.
- To provide data supporting the co-administration of imipenem/cilastatin/relebactam with other antimicrobials.
Main Methods:
- Physical characteristics, pH, and turbidity were measured for 2-drug admixtures.
- Imipenem/cilastatin/relebactam was combined with a wide range of antimicrobial agents.
- Compatibility was assessed after admixture at a specific time point.
Main Results:
- Imipenem/cilastatin/relebactam demonstrated compatibility with a broad spectrum of antimicrobial agents.
- Exceptions included amphotericin B deoxycholate and posaconazole.
- No significant physical incompatibilities were observed with compatible agents.
Conclusions:
- Y-site administration of imipenem/cilastatin/relebactam with most antimicrobials is feasible.
- This compatibility facilitates hospital protocol integration and therapy optimization.
- Co-administration can reduce total infusion time, optimize PK/PD, and contain costs.
More Related Videos
12:03Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
Published on: April 18, 2019
11:15Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
Published on: July 24, 2021
Related Concept Videos
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Acute Pyelonephritis II: Diagnostic Studies and Management
Antibiotic Selection
Dosage Interval and Administration Route: Determination Methods
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence